| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Department of Otolaryngology/Head and Neck Surgery, University Hospital Vrije Universiteit [M. B. V., M. S., G. B. S., G. A. M. S. v. D.]; Radio Nuclide Center, Vrije Universiteit [G. W. M. V.]; and Division of Experimental Therapy, Netherlands Cancer Institute/Antoni van Leeuwenhoek Huis [H. O.], 1081 HV Amsterdam, the Netherlands
The use of monoclonal antibodies (MAbs) directed against tumor-associated antigens for targeting of photosensitizers is an interesting option to improve the selectivity of photodynamic therapy (PDT). Hydrophilic photosensitizers are most suitable for conjugation to MAbs because of their water solubility. The photosensitizer aluminum (III) phthalocyanine tetrasulfonate [AlPc(SO3H)4] has many ideal photochemical properties; however, because of its hydrophilicity, the free form of this sensitizer does not readily reach the critical intracellular target and, therefore, is ineffective in PDT. On the basis of our previous studies, we hypothesized that AlPc(SO3H)4 might be suitable for PDT when coupled to internalizing tumor-selective MAbs. In this study, a reproducible procedure is presented for coupling of AlPc(SO3H)4 to MAbs via the tetra-glycine derivative AlPc(SO2Ngly)4. Conjugation was performed to chimeric MAb (cMAb) U36 and murine MAbs (mMAb) E48 and 425 using a labile ester. Conjugates showed preservation of integrity and immunoreactivity and full stability in serum in vitro. At molar ratios >4, the solubility of the conjugates decreased. Data on the in vitro efficacy of PDT showed that in the chosen experimental setup the internalizing AlPc(SO2Ngly)4-mMAb 425 conjugate was about 7500 times more toxic to A431 cells than the free sensitizer (IC50s, 0.12 nM versus 900 nM). The AlPc(SO2Ngly)4-mMAb 425 conjugate was also more toxic than meta-tetrahydroxyphenylchlorin-mMAb 425 conjugates and free meta-tetrahydroxyphenylchlorin that had been tested previously (M. B. Vrouenraets et al., Cancer Res., 59: 1505–1513, 1999) in the same system (IC50s, 7.3 nM and 2.0 nM, respectively). Biodistribution analysis of AlPc(SO2Ngly)4-125I-labeled cMAb U36 conjugates with different sensitizer:MAb ratios in squamous cell carcinoma-bearing nude mice revealed selective accumulation in the tumor, although to a lesser extent than for the unconjugated 125I-labeled cMAb U36, whereas tumor:blood ratios were similar. These findings indicate that AlPc(SO3H)4 has high potential for use in PDT when coupled to internalizing tumor-selective MAbs.
This article has been cited by other articles:
|
|
 |
|
  M. D. Savellano, B. W. Pogue, P. J. Hoopes, E. S. Vitetta, and K. D. Paulsen Multiepitope HER2 Targeting Enhances Photoimmunotherapy of HER2-Overexpressing Cancer Cells with Pyropheophorbide-a Immunoconjugates Cancer Res., July 15, 2005; 65(14): 6371 - 6379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Savellano and T. Hasan Photochemical Targeting of Epidermal Growth Factor Receptor: A Mechanistic Study Clin. Cancer Res., February 15, 2005; 11(4): 1658 - 1668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Verel, G. W.M. Visser, R. Boellaard, M. Stigter-van Walsum, G. B. Snow, and G. A.M.S van Dongen 89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies J. Nucl. Med., August 1, 2003; 44(8): 1271 - 1281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Pitsillides, E. K. Joe, X. Wei, R. R. Anderson, and C. P. Lin Selective Cell Targeting with Light-Absorbing Microparticles and Nanoparticles Biophys. J., June 1, 2003; 84(6): 4023 - 4032. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
